Atossa Therapeutics (ATOS) News Today $0.89 -0.03 (-3.13%) Closing price 06/10/2025 04:00 PM EasternExtended Trading$0.87 -0.01 (-1.41%) As of 06/10/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATOS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Atossa Therapeutics (NASDAQ:ATOS) Stock Price Expected to Rise, Ascendiant Capital Markets Analyst SaysJune 7, 2025 | americanbankingnews.comAtossa Therapeutics (NASDAQ:ATOS) Given New $7.50 Price Target at Ascendiant Capital MarketsAscendiant Capital Markets raised their price objective on shares of Atossa Therapeutics from $7.25 to $7.50 and gave the company a "buy" rating in a research report on Friday.June 6, 2025 | marketbeat.comCraig-Hallum Initiates Coverage of Atossa Therapeutics (ATOS) with Buy RecommendationJune 6, 2025 | msn.comCraig Hallum Begins Coverage on Atossa Therapeutics (NASDAQ:ATOS)Craig Hallum started coverage on shares of Atossa Therapeutics in a research note on Thursday. They issued a "buy" rating and a $4.00 price objective on the stock.June 5, 2025 | marketbeat.comAtossa Therapeutics to Present at the Jefferies Global Healthcare ConferenceJune 2, 2025 | prnewswire.comAtossa Therapeutics Reports Q1 2025 Financial ResultsMay 27, 2025 | tipranks.comAtossa Therapeutics (NASDAQ:ATOS) Stock Price Passes Above 200-Day Moving Average - Time to Sell?Atossa Therapeutics (NASDAQ:ATOS) Share Price Passes Above 200 Day Moving Average - Time to Sell?May 24, 2025 | marketbeat.comAtossa Therapeutics CEO Steven Quay buys $9,886 in common stockMay 24, 2025 | investing.comAtossa Therapeutics, Inc.: Join Atossa Therapeutics' Exclusive Live Investor Webinar and Q&A Session on May 22May 20, 2025 | finanznachrichten.deAtossa Therapeutics (NASDAQ:ATOS) Issues Earnings ResultsAtossa Therapeutics (NASDAQ:ATOS - Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.05) EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.01.May 15, 2025 | marketbeat.comAtossa Therapeutics (NASDAQ:ATOS) Stock Crosses Below 200-Day Moving Average - Here's WhyAtossa Therapeutics (NASDAQ:ATOS) Share Price Crosses Below Two Hundred Day Moving Average - Here's WhyMay 15, 2025 | marketbeat.comAtossa Therapeutics Inc: Atossa Therapeutics Announces Full Results from I-SPY 2 Endocrine-Optimization Sub-Study Evaluating Low-Dose (Z)-EndoxifenMay 14, 2025 | finanznachrichten.deAtossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑EndoxifenMay 14, 2025 | finance.yahoo.comAtossa Therapeutics Announces Full Results from I‑SPY 2 Endocrine‑Optimization Sub‑Study Evaluating Low‑Dose (Z)‑EndoxifenMay 14, 2025 | prnewswire.comAtossa Therapeutics Inc: Atossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate UpdateMay 13, 2025 | finanznachrichten.deAtossa Therapeutics Announces First Quarter 2025 Financial Results and Provides a Corporate UpdateMay 13, 2025 | prnewswire.comAtossa Therapeutics (ATOS) to Release Quarterly Earnings on MondayAtossa Therapeutics (NASDAQ:ATOS) will be releasing its Q1 2025 earnings before the market opens on Monday, May 12. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-12-atossa-therapeutics-inc-stock/)May 7, 2025 | marketbeat.comAtossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen PortfolioApril 30, 2025 | globenewswire.comAtossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025April 29, 2025 | finance.yahoo.comAtossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025April 29, 2025 | globenewswire.comAscendiant Capital Markets Predicts ATOS Q1 EarningsAtossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) - Analysts at Ascendiant Capital Markets issued their Q1 2026 EPS estimates for Atossa Therapeutics in a research note issued on Sunday, April 20th. Ascendiant Capital Markets analyst E. Woo expects that the company will post earnings per sharApril 25, 2025 | marketbeat.comAtossa Therapeutics secures new patent for breast cancer treatmentApril 24, 2025 | uk.investing.comPRISM Mid-Day Movers: Board Shakeups and Biotech Financings Drive Investor FocusApril 23, 2025 | theglobeandmail.comAtossa Therapeutics announces issuance of U.S. patentApril 23, 2025 | markets.businessinsider.comAtossa Therapeutics (NASDAQ:ATOS) Given New $7.25 Price Target at Ascendiant Capital MarketsAscendiant Capital Markets boosted their price objective on shares of Atossa Therapeutics from $7.00 to $7.25 and gave the company a "buy" rating in a report on Monday.April 23, 2025 | marketbeat.comAtossa Therapeutics Announces Issuance of U.S. Patent No. 12,275,684, Further Strengthening (Z)-endoxifen PortfolioApril 22, 2025 | globenewswire.comNona Biosciences Inks Research Partnership With Atossa Therapeutics For Next-gen Breast Cancer DrugsApril 12, 2025 | nasdaq.comAtossa Therapeutics and Nona Biosciences partner in breast cancer antibodiesApril 11, 2025 | markets.businessinsider.comNona Biosciences, Atossa Partner on Next-Gen Breast Cancer Antibody TherapiesApril 11, 2025 | msn.comNona Biosciences and Atossa Therapeutics Partner to Discover Next-Generation Antibody Therapies for Breast CancerApril 10, 2025 | prnewswire.comAtossa Therapeutics (ATOS) Projected to Post Quarterly Earnings on MondayAtossa Therapeutics (NASDAQ:ATOS) will be releasing earnings before the market opens on Monday, April 7, Financial Modeling Prep reports.March 31, 2025 | marketbeat.comQ1 EPS Forecast for Atossa Therapeutics Boosted by AnalystAtossa Therapeutics, Inc. (NASDAQ:ATOS - Free Report) - Research analysts at HC Wainwright upped their Q1 2025 EPS estimates for Atossa Therapeutics in a research note issued to investors on Tuesday, March 25th. HC Wainwright analyst E. Bodnar now anticipates that the company will post earnings oMarch 29, 2025 | marketbeat.comAtossa Therapeutics’ Earnings Call Highlights Cost Reductions and Clinical ProgressMarch 28, 2025 | tipranks.comAtossa Therapeutics (NASDAQ:ATOS) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and set a $7.00 price target on shares of Atossa Therapeutics in a research report on Wednesday.March 27, 2025 | marketbeat.comAtossa Therapeutics, Inc. (ATOS) Q4 2024 Earnings Call TranscriptMarch 27, 2025 | seekingalpha.comAtossa Therapeutics reports Q4 EPS (20c), consensus (22c)March 27, 2025 | markets.businessinsider.comQ4 2024 Atossa Therapeutics Inc Earnings CallMarch 26, 2025 | uk.finance.yahoo.comWe Think Atossa Therapeutics (NASDAQ:ATOS) Can Afford To Drive Business GrowthMarch 26, 2025 | finance.yahoo.comAtossa Therapeutics (NASDAQ:ATOS) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPSAtossa Therapeutics (NASDAQ:ATOS - Get Free Report) announced its quarterly earnings data on Tuesday. The company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01.March 26, 2025 | marketbeat.comAtossa Therapeutics Reports 2024 Financial Results and UpdatesMarch 26, 2025 | tipranks.comAtossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate UpdateMarch 25, 2025 | markets.businessinsider.comAtossa Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate UpdateMarch 25, 2025 | globenewswire.comAtossa Therapeutics (ATOS) to Release Earnings on TuesdayAtossa Therapeutics (NASDAQ:ATOS) will be releasing earnings on Tuesday, March 25, Financial Modeling Prep reports.March 22, 2025 | marketbeat.comAtossa Therapeutics to Report Fourth Quarter and Full Year 2024 Financial ResultsMarch 20, 2025 | globenewswire.comAtossa Therapeutics (NASDAQ:ATOS) Earns "Buy" Rating from HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $7.00 price target on shares of Atossa Therapeutics in a research report on Wednesday.March 13, 2025 | marketbeat.comDoes Sugar Feed Cancer? Here’s What the Latest Science SaysMarch 11, 2025 | yahoo.comAtossa Therapeutics to pursue metastatic breast cancer for (Z)-endoxifenMarch 11, 2025 | markets.businessinsider.comAtossa Therapeutics Announces Plans to Pursue Metastatic Breast Cancer Indication for (Z)-Endoxifen and Continued Engagement with FDA on Additional IndicationsMarch 11, 2025 | globenewswire.comAtossa Therapeutics faces Nasdaq delisting over bid priceFebruary 26, 2025 | investing.comSen. Roger Marshall introduces bill to ban federal grants for ‘dangerous’ gain-of-function researchFebruary 26, 2025 | msn.com Get Atossa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address ATOS Media Mentions By Week ATOS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATOS News Sentiment▼0.871.01▲Average Medical News Sentiment ATOS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATOS Articles This Week▼72▲ATOS Articles Average Week Get Atossa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ORKA News RAPP News ERAS News DNA News TECX News ATAI News UPXI News TNGX News SEPN News PGEN News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATOS) was last updated on 6/11/2025 by MarketBeat.com Staff From Our PartnersTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atossa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atossa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATOS Stock Free ATOS Stock Alerts